VYNE Therapeutics Inc

NASDAQ:VYNE   11:09:20 AM EDT
1.13
-0.01 (-0.88%)
Earnings Announcements

VYNE Therapeutics Reports Third Quarter 2021 Financial Results

Published: 11/10/2021 12:45 GMT
VYNE Therapeutics Inc (VYNE) - Vyne Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update.
Q3 Revenue $4.1 Million.
Phase 2a Results for Fmx114 in Mild-to-moderate Atopic Dermatitis Expected Early Q1 2022.
Qtrly Diluted Net Loss per Share $0.41.
Qtrly Adjusted Diluted Net Loss per Share $0.36.
Q3 Earnings per Share View $-0.32, Revenue View $4.8 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $4.12 Million
Adjusted EPS is expected to be -$0.25

Next Quarter Revenue Guidance is expected to be $0.3 Million
Next Quarter EPS Guidance is expected to be -$0.16

More details on our Analysts Page.